Lilly delays submission to market once-daily diabetes drug
February 23, 2015 at 08:55 AM EST
Feb 23 (Reuters) - Eli Lilly and Co said it would delay its application to market its once-daily diabetes treatment, basal insulin peglispro, beyond the current quarter.